Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Uncle Mikey who wrote (109)	11/11/1997 4:17:00 PM
From: Ron Kline	Respond to of 340

Well with all stocks down it looks like anyone who didn't buy in April's lows are having their stocks go below their buy price. The question now becomes when do we average down. It seems like this can be done too quickly and result in lower prices even further. Any ideas where support could be very strong for the longer term investor. I thought I got in at the low of the 50's. Oh this Damn market, they do it to us long termers at least 2 times a year. I'm beginning to think long term means long pain. Ron

To: Uncle Mikey who wrote (109)	11/11/1997 11:29:00 PM
From: James Silverman	Read Replies (1) \| Respond to of 340

As far as I can tell, Copaxone is doing fine. Because Teva is unlike many US and Canadian counterparts and not prone to hype, they are taking their time before revealing Copaxone numbers. This has created worry. I see the stock doing quite fine in 1998 as it becomes evident that copaxone indeed will contribute nicely to Teva's bottom line.

To: Uncle Mikey who wrote (109)	11/12/1997 3:43:00 AM
From: Gary105	Read Replies (1) \| Respond to of 340

Re. Natwest, Copaxone in best case scenario contributes a little over 30 cents a share to earnings. So if Copaxone does not sell at all, Teviy consensus for next yr goes to about $3.10 (highly unlikely). If it sells modestly, maybe $3.25 and if it sells as planned $3.37 based on consensus. So the impact of Copaxone is overdone - plus it will probably sell. If anyone knows of a pharmaceutical company growing at 50%/yr selling at 15x next years earnings, please let me know. Gary